AbbVie's positive eczema study drags down Regeneron's shares

(Reuters) - AbbVie Inc said on Thursday its experimental drug to treat adults with moderate-to-severe eczema met the main goal in a mid-stage study, dragging down shares of rival U.S. biotech firm Regeneron Pharmaceuticals Inc.

Source: Reuters: Health - September 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news